Skip to main content

Here’s how the ‘pause’ on J&J’s COVID-19 shot may affect the company’s earnings

To what degree will Johnson & Johnson’s COVID-19 vaccine manufacturing issues and the federal 'pause' over safety concerns weigh on investors' mind when the company reports earnings next week?
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.